Cargando…

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer

PURPOSE: We aimed to investigate the feasibility of droplet digital PCR (ddPCR) for the quantitative and dynamic detection of EGFR mutations and next generation sequencing (NGS) for screening EGFR-tyrosine kinase inhibitors (EGFR-TKIs) resistance-relevant mutations in circulating tumor DNA (ctDNA) f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xue, Zhuo, Minglei, Ye, Xin, Bai, Hua, Wang, Zhijie, Sun, Yun, Zhao, Jun, An, Tongtong, Duan, Jianchun, Wu, Meina, Wang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991494/ https://www.ncbi.nlm.nih.gov/pubmed/26989078 http://dx.doi.org/10.18632/oncotarget.8021

Ejemplares similares

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
por: Wang, Zhijie, et al.
Publicado: (2014)

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung
por: Duan, Jianchun, et al.
Publicado: (2015)

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
por: Zhu, Jian, et al.
Publicado: (2012)

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer
por: Bai, Hua, et al.
Publicado: (2013)

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
por: Wang, Shuhang, et al.
Publicado: (2015)

Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer
por: Duan, Jianchun, et al.
Publicado: (2017)

Efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel for non‐small cell lung cancer patients who have failed at least two prior systemic treatments
por: Duan, Jianchun, et al.
Publicado: (2017)

Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer
por: Lv, Chunxin, et al.
Publicado: (2018)

Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer
por: Wang, Shuhang, et al.
Publicado: (2013)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
por: Dong, Yiting, et al.
Publicado: (2022)

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma
por: Wang, Shuhang, et al.
Publicado: (2020)

The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer
por: Chen, Hanxiao, et al.
Publicado: (2022)

High‐fidelity of non‐small cell lung cancer xenograft models derived from bronchoscopy‐guided biopsies
por: Fu, Shuai, et al.
Publicado: (2015)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study
por: Yang, Xue, et al.
Publicado: (2021)

Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma
por: Li, Zhenxiang, et al.
Publicado: (2015)

NGMA-1. Quantification of IDH mutant alleles predicts outcome in diffuse gliomas
por: Voisin, Mathew, et al.
Publicado: (2021)

Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma
por: Zhong, Jia, et al.
Publicado: (2018)

Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience
por: Wang, Lu, et al.
Publicado: (2020)

Hypoxia‐inducible factor‐1α and nuclear factor‐κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non‐small‐cell lung cancer cells
por: Guo, Rong, et al.
Publicado: (2019)

Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database
por: Zhuo, Minglei, et al.
Publicado: (2019)

KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients
por: Wang, Zhe-Ying, et al.
Publicado: (2019)

Quantification of mutant–allele expression at isoform level in cancer from RNA-seq data
por: Deng, Wenjiang, et al.
Publicado: (2022)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database
por: Wang, Yuyan, et al.
Publicado: (2020)

Can double PPO mutations exist in the same allele and are such mutants functional?
por: Porri, Aimone, et al.
Publicado: (2022)

Mutant-allele fraction heterogeneity is associated with non-small cell lung cancer patient survival
por: Shen, Sipeng, et al.
Publicado: (2018)

Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy
por: Zhao, Jie, et al.
Publicado: (2023)

Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients
por: Zhuo, Minglei, et al.
Publicado: (2020)

Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA
por: Bos, Manouk K., et al.
Publicado: (2020)

Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
por: Li, Jianjie, et al.
Publicado: (2021)

The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis
por: Zhao, Zhe, et al.
Publicado: (2020)

Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer
por: Zhao, Zhe, et al.
Publicado: (2020)

Characterization of a Weak Allele of Zebrafish cloche Mutant
por: Ma, Ning, et al.
Publicado: (2011)

Optimal first‐line treatment for advanced thymic carcinoma
por: Yang, Xue, et al.
Publicado: (2019)

Allele-specific gene expression can underlie altered transcript abundance in zebrafish mutants
por: White, Richard J, et al.
Publicado: (2022)

Survival comparison of right and left side non‐small cell lung cancer in stage I–IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysis
por: Jia, Bo, et al.
Publicado: (2019)

Corrigendum to: Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA
Publicado: (2021)

Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells
por: Lei, Kefeng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p08i34fe6u8cjnc38b5kb7g7qu